Invention Grant
- Patent Title: 1,3,4-thiadiazole compounds and their use in treating cancer
-
Application No.: US16402825Application Date: 2019-05-03
-
Publication No.: US10981904B2Publication Date: 2021-04-20
- Inventor: Johannes Wilhelmus Maria Nissink , Maurice Raymond Verschoyle Finlay , Mark David Charles
- Applicant: Cancer Research Technology Limited
- Applicant Address: GB London
- Assignee: Cancer Research Technology Limited
- Current Assignee: Cancer Research Technology Limited
- Current Assignee Address: GB London
- Agency: McCarter & English, LLP
- Agent Steven G. Davis; Wei Song
- Main IPC: C07D417/14
- IPC: C07D417/14

Abstract:
A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
Public/Granted literature
- US20190389853A1 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer Public/Granted day:2019-12-26
Information query